NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Price, News & Analysis $5.78 +0.25 (+4.52%) Closing price 04:00 PM EasternExtended Trading$5.75 -0.03 (-0.54%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About ORIC Pharmaceuticals Stock (NASDAQ:ORIC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ORIC Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.32▼$5.9850-Day Range$5.53▼$12.5452-Week Range$5.25▼$14.67Volume647,091 shsAverage Volume616,321 shsMarket Capitalization$410.54 millionP/E RatioN/ADividend YieldN/APrice Target$18.86Consensus RatingBuy Company OverviewORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More… Remove Ads ORIC Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreORIC MarketRank™: ORIC Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 184th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageORIC Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ORIC Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ORIC Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.82% of the float of ORIC Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 3.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.16 Percentage of Shares Shorted20.82% of the float of ORIC Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 3.18%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.75 News SentimentORIC Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ORIC Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.55% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ORIC Pharmaceuticals' insider trading history. Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Stock News HeadlinesORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMarch 31 at 4:30 PM | globenewswire.comOppenheimer Remains a Buy on Zentalis Pharmaceuticals (ZNTL)March 27, 2025 | markets.businessinsider.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 2, 2025 | American Alternative (Ad)ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fulgent Genetics (FLGT), Alignment Healthcare (ALHC) and Syndax Pharmaceuticals (SNDX)March 4, 2025 | markets.businessinsider.comOric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114February 26, 2025 | markets.businessinsider.comOric Pharmaceuticals (ORIC) Gets a Buy from OppenheimerFebruary 26, 2025 | markets.businessinsider.comSee More Headlines ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? ORIC Pharmaceuticals' stock was trading at $8.07 on January 1st, 2025. Since then, ORIC stock has decreased by 28.4% and is now trading at $5.78. View the best growth stocks for 2025 here. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) released its quarterly earnings data on Tuesday, February, 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01. When did ORIC Pharmaceuticals IPO? ORIC Pharmaceuticals (ORIC) raised $75 million in an IPO on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ORIC Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings2/18/2025Today4/02/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORIC CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$18.86 High Stock Price Target$22.00 Low Stock Price Target$14.00 Potential Upside/Downside+219.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.54% Return on Assets-40.72% Debt Debt-to-Equity RatioN/A Current Ratio10.56 Quick Ratio13.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book1.73Miscellaneous Outstanding Shares71,027,000Free Float67,085,000Market Cap$419.77 million OptionableOptionable Beta1.25 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ORIC) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.